Kerendia Tab, a new drug for chronic kidney disease with diabetes mellitus that was reimbursed in February this year, was added to the list of low-content multiple-dose prescription reimbursement cuts.

As the price for the high and low-dose formulations were set the same for the drug, there is virtually no incentive to prescribe multiple doses.

According to industry sources 18th, the Health Insurance Review and Assessment Service on Monday added Kerendia (finerenone, Bayer) to its list of cost-effective formularies.

The price of Kerendia 10 mg and Kerendia 20 mg are the same at 1,670 won per tablet.

It is indicated as a treatment for adult patients